EUVIMEDEUVIMED entdecken
Multizentrische Studie

Tenofovir alafenamide or tenofovir disoproxil fumarate in pregnancy to prevent HBV transmission: Maternal ALT trajectory and infant outcomes

Huey-Ling Chen iD, Chien-Nan Lee, Chin-Hao Chang, Ming-Wei Lai, Ming-Chieh Tsai, Shu-Chi Mu, Chun-Jen Liu, Jin-Chung Shih, Wan-Hsin Wen iD, Rui-Ting Hu, Chun-Pin Huang, Kuang-Chun Hu und 8 weitere

Liver International · 2024

DOI: 10.1111/liv.15873 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Liver International, 2024. Verfasst von Huey-Ling Chen und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, National Taiwan University College of Medicine and Children's Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Tenofovir, Infectious Disease Transmission, Vertical, Antiviral Agents, Pregnancy Complications, Infectious. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Taiwan Centers for Disease Control, Ministry of Health and Welfare, Taiwan, Gilead Sciences, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The use of antiviral agents, specifically tenofovir disoproxil fumarate (TDF), in pregnant women to prevent mother‐to‐child HBV transmission is a key step towards hepatitis elimination. However, data on using tenofovir alafenamide (TAF) is insufficient. The frequent occurrence of postpartum ALT flares may impact the clinical implementation.

Methods

The maternal and infant outcomes were compared in multi‐centre trials of high viral load HBsAg/HBeAg+ pregnant women receiving TAF or TDF from the third trimester until 2 weeks postpartum with intensive follow‐ups. To explore the dynamic pre‐ and postpartum changes in ALT levels, we used a group‐based trajectory model for analysing data of 332 women from three prospective studies.

Results

After treatment, the maternal HBV DNA levels significantly decreased from baseline to delivery: 7.87 ± 0.59 to 3.99 ± 1.07 Log 10 IU/mL TAF ( n = 78) and 8.30 ± 0.36 to 4.47 ± 0.86 Log 10 IU/mL (TDF, n = 53), with viral load reductions of 3.87 versus 3.83 Log 10 IU/mL. The HBsAg‐positive rates among 12‐month‐old infants were 1.28% (1/78) versus 1.82% (1/55) respectively ( p = 1.00). Of the TAF or TDF‐treated mothers, 25.64% versus 16.98% experienced ALT > 2X ULN, and 11.54% versus 1.89% received extended antiviral treatment. Our model revealed four distinct ALT patterns: stable ALT (87.2%), moderate (8.0%) or marked (2.4%) postpartum flares, or prepartum elevations (2.4%).

Conclusions

TAF effectively reduces mother‐to‐child HBV transmission, but prophylaxis failure still occurred in few cases. Postpartum ALT flares are common in women receiving TAF or TDF during pregnancy. Approximately 12.8% of mothers may require extended postpartum antiviral treatment. Clinical trial number: NCT03695029 (ClinicalTrials.gov).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TenofovirInfectious Disease Transmission, VerticalAntiviral AgentsPregnancy Complications, InfectiousViral LoadAlanineAlanine TransaminaseHumansFemalePregnancyAdultProspective StudiesInfant, NewbornHepatitis BAdenineHepatitis B virusDNA, ViralInfant

Stichwörter der Autor:innen

HBV immunizationHBeAgantiviral therapychildrenhepatitis B virusmother‐to‐infant transmissionnucleoside analoguepregnancypregnant women

Substanzen

TenofovirAntiviral AgentsAlanineAlanine TransaminaseAdenineDNA, Viraltenofovir alafenamide

Autor:innen und Institutionen

  • Department of Pediatrics, National Taiwan University College of Medicine and Children's Hospital, Taipei, Taiwan.
  • Department and Graduate Institute of Medical Education and Bioethics, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan.
  • Department of Obstetrics and Gynecology, National Taiwan University College of Medicine and Hospital, Taipei, Taiwan.
  • Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.
  • Division of Pediatric Gastroenterology, Department of Pediatrics, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.

ORCID-Profile: Huey-Ling Chen, Wan-Hsin Wen, Hong-Yuan Hsu, Yen-Hsuan Ni, Mei-Hwei Chang

Förderung

  • Taiwan Centers for Disease Control
  • Ministry of Health and Welfare, Taiwan
  • Gilead Sciences, Inc.
  • Ministry of Health and Welfare
  • Gilead Sciences

Zitieren

APA

Chen, H. L., Lee, C. N., Chang, C. H., Lai, M. W., Tsai, M. C., Mu, S. C., Liu, C. J., Shih, J. C., Wen, W. H., Hu, R. T., Huang, C. P., Hu, K. C., Chen, C. P., Lee, C. L., Chien, R. N., Chang, K. C., Hsu, H. Y., Lee, C. C., Ni, Y. H., & Chang, M. H. (2024). Tenofovir alafenamide or tenofovir disoproxil fumarate in pregnancy to prevent HBV transmission: Maternal ALT trajectory and infant outcomes. Liver International. https://doi.org/10.1111/liv.15873

Vancouver

Chen HL, Lee CN, Chang CH, Lai MW, Tsai MC, Mu SC, et al. Tenofovir alafenamide or tenofovir disoproxil fumarate in pregnancy to prevent HBV transmission: Maternal ALT trajectory and infant outcomes. Liver International. 2024. doi:10.1111/liv.15873

BibTeX
@article{Chen2024,
  author = {Chen, Huey-Ling and Lee, Chien-Nan and Chang, Chin-Hao and Lai, Ming-Wei and Tsai, Ming-Chieh and Mu, Shu-Chi and Liu, Chun-Jen and Shih, Jin-Chung and Wen, Wan-Hsin and Hu, Rui-Ting and Huang, Chun-Pin and Hu, Kuang-Chun and Chen, Chie-Pein and Lee, Chyi-Long and Chien, Rong-Nan and Chang, Kai-Chi and Hsu, Hong-Yuan and Lee, Chien-Chang and Ni, Yen-Hsuan and Chang, Mei-Hwei},
  title = {Tenofovir alafenamide or tenofovir disoproxil fumarate in pregnancy to prevent HBV transmission: Maternal ALT trajectory and infant outcomes},
  journal = {Liver International},
  year = {2024},
  doi = {10.1111/liv.15873}
}
Kostenlos starten →